JUNO THERAPEUTICS INC (JUNO) Stock Price & Overview
NASDAQ:JUNO • US48205A1097
Current stock price
The current stock price of JUNO is 86.96 null. Today JUNO is up by 0.1%. In the past month the price increased by 1.59%. In the past year, price increased by 286.83%.
JUNO Key Statistics
- Market Cap
- 10.097B
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -4.10
- Dividend Yield
- N/A
JUNO Stock Performance
JUNO Stock Chart
JUNO Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to JUNO. When comparing the yearly performance of all stocks, JUNO is one of the better performing stocks in the market, outperforming 99.03% of all stocks.
JUNO Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to JUNO. JUNO scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
JUNO Earnings
JUNO Forecast & Estimates
JUNO Financial Highlights
Over the last trailing twelve months JUNO reported a non-GAAP Earnings per Share(EPS) of -4.0972. The EPS decreased by -69.3% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | -390.72% | ||
| ROA | -30.46% | ||
| ROE | -41.75% | ||
| Debt/Equity | 0.01 |
JUNO Ownership
About JUNO
Company Profile
Juno Therapeutics, Inc. is a biopharmaceutical company. The Company develops cellular immunotherapies based on two platforms - Chimeric Antigen Receptors (CARs) and T Cell Receptors (TCRs) technologies. Its clinical CD19 product candidates include JCAR015 that is in Phase I clinical trials for adult patients with relapsed/refractory B cell acute lymphoblastic leukemia (r/r ALL); JCAR017, which is in Phase I/II trials for pediatric patients with r/r ALL whose cancer has recurred after a bone marrow transplant; and JCAR014 that is in Phase I/II trials to treat various B cell malignancies in patients relapsed or refractory to standard therapies. Juno Therapeutics, Inc. is headquartered in Seattle, Washington.
Company Info
JUNO THERAPEUTICS INC
400 DEXTER AVENUE NORTH SUITE 1200
SEATTLE WA 98109
CEO: Hans E. Bishop
Phone: 206-582-1600
JUNO THERAPEUTICS INC / JUNO FAQ
What does JUNO THERAPEUTICS INC do?
Juno Therapeutics, Inc. is a biopharmaceutical company. The Company develops cellular immunotherapies based on two platforms - Chimeric Antigen Receptors (CARs) and T Cell Receptors (TCRs) technologies. Its clinical CD19 product candidates include JCAR015 that is in Phase I clinical trials for adult patients with relapsed/refractory B cell acute lymphoblastic leukemia (r/r ALL); JCAR017, which is in Phase I/II trials for pediatric patients with r/r ALL whose cancer has recurred after a bone marrow transplant; and JCAR014 that is in Phase I/II trials to treat various B cell malignancies in patients relapsed or refractory to standard therapies. Juno Therapeutics, Inc. is headquartered in Seattle, Washington.
What is the current price of JUNO stock?
The current stock price of JUNO is 86.96 null. The price increased by 0.1% in the last trading session.
Does JUNO stock pay dividends?
JUNO does not pay a dividend.
What is the ChartMill technical and fundamental rating of JUNO stock?
JUNO has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What is JUNO THERAPEUTICS INC worth?
JUNO THERAPEUTICS INC (JUNO) has a market capitalization of 10.10B null. This makes JUNO a Large Cap stock.